HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
XBIO
Xenetic Biosciences, Inc.
There isn't enough reported data to score XBIO yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
XBIO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Unavailable |
XBIO's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
XBIO PE Valuation
XBIO has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
XBIO Forward outlook
There aren't enough analyst estimates for XBIO to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
XBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.54 | +$0.51 |
| Q2 2026 | -$1.15 | +$0.85 |
| Q1 2026 | -$1.19 | +$1.19 |
| Q4 2025 | -$1.58 | +$0.99 |
| Q3 2025 | -$2.05 | +$0.57 |
| Q2 2025 | -$2.00 | +$1.03 |
| Q1 2025 | -$2.38 | +$0.51 |
| Q4 2024 | -$2.57 | +$0.14 |
XBIO has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over XBIO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over XBIO on profitability, with a higher operating margin.
XBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $725.3K | -29% |
| Q2 2026 | $660.6K | +12% |
| Q1 2026 | $806.9K | +36% |
| Q4 2025 | $766.3K | +18% |
| Q3 2025 | $1M | +67% |
| Q2 2025 | $589.9K | -19% |
| Q1 2025 | $593.3K | +16% |
| Q4 2024 | $648.8K | -3.4% |
XBIO's revenue fell from its 2025 peak and has held roughly level since: $725,257 last quarter, down 29% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -240% | -187 points |
| Q2 2026 | -147% | -24 points |
| Q1 2026 | -62% | +97 points |
| Q4 2025 | -81% | +88 points |
| Q3 2025 | -53% | +28 points |
| Q2 2025 | -123% | +61 points |
| Q1 2025 | -159% | +90 points |
| Q4 2024 | -169% | +18 points |
XBIO's operating margin was −240% last quarter, down 187 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over XBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
XBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$662.1K | -$3.9K |
| Q2 2026 | -$875.5K | -$491.7K |
| Q1 2026 | -$536.4K | +$465.5K |
| Q4 2025 | -$242.7K | +$431.3K |
| Q3 2025 | -$658.2K | -$199.2K |
| Q2 2025 | -$383.8K | +$141.3K |
| Q1 2025 | -$1M | +$157.5K |
| Q4 2024 | -$674K | +$119K |
XBIO has burned cash in almost every quarter: −$2M over the past year, against −$3M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over XBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
XBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +48.8K shares |
| 1 year | +52% | +801K shares |
| 3 years | +54% | +818K shares |
| 5 years | +168% | +1.5M shares |
| Available history | +276% | +1.7M shares |
XBIO has 2M diluted shares, up 52% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
XBIO Net Leverage
XBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
XBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 8.3 | Oversold |
XBIO's weekly RSI is 37 (neutral) and its Stochastic is 8 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
XBIO PE vs Healthcare Sector
XBIO has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
XBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.01 | 17% below |
| 20 week MA | $2.74 | 39% below |
| 50 week MA | $2.72 | 39% below |
| 100 week MA | $3.06 | 46% below |
| 200 week MA | $3.54 | 53% below |
XBIO is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
XBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.3 | $21.9 | +53% |
| 2021 | $21.9 | $14.4 | -34% |
| 2022 | $14.4 | $3.10 | -78% |
| 2023 | $3.10 | $3.45 | +11% |
| 2024 | $3.45 | $4.11 | +19% |
| 2025 | $4.11 | $2.08 | -49% |
| 2026 YTD | $2.08 | $1.66 | -20% |
XBIO has the edge over HIMS on returns for 2026, with the stronger performance.